The United Nations Population Fund (UNFPA) has issued its 9th Invitation to Manufacturers of Reproductive Health Medicines to Submit an Expression of Interest (EOI) for Product Evaluation by the WHO Expert Review Panel (ERP). The official invitation can be found here.
The ERP was created to ensure supply of quality products in the short-term, giving risk-based advice on products that are in the SRA or WHO PQ ‘pipeline’ but have not yet been approved or prequalified. This allows procurement organisations to make evidence-based decisions on the products that have been submitted for evaluation.
The products included in this EOI are oral hormonal contraceptives, injectable hormonal contraceptives, implantable contraceptives, oxytoxics, and products for prevention and treatment of eclampsia.
More information on WHO Prequalification can be found on our Resources page.